Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
6
Bullish
2
Bearish
25
Neutral
6
Bullish
15
Bearish
19
Neutral
0
Bullish
13
Dishman Carbogen Amcis Limited is a global CDMO specializing in complex active pharmaceutical ingredients (APIs) and high active ingredients, serving biotech and pharmaceutical markets.
The company is expanding its integrated CDMO capabilities with ongoing expansions at facilities in Switzerland, France, and India to accommodate rising customer demands.
Recent financial performance has shown improvement, despite certain deferrals in revenue due to supply chain delays, indicating robust operational resilience.
The company's strategy includes significant focus on oncology drugs, showcasing leadership in high-potency ingredients, supported by successful developments in ADC and Vitamin D analogues.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,672 Cr
High Risk
165.4
37.5
0.1
0.4
321.15
129.00
Sales CAGR
Profit CAGR
ROE
ROCE
Dishman Carbogen Amcis Ltd (DCAL) is currently trading at 170.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dishman Carbogen Amcis Limited is a global CDMO specializing in complex active pharmaceutical ingredients (APIs) and high active ingredients, serving biotech and pharmaceutical markets. The company is expanding its integrated CDMO capabilities with ongoing expansions at facilities in Switzerland, France, and India to accommodate rising customer demands. Recent financial performance has shown improvement, despite certain deferrals in revenue due to supply chain delays, indicating robust operational resilience. The company's strategy includes significant focus on oncology drugs, showcasing leadership in high-potency ingredients, supported by successful developments in ADC and Vitamin D analogues.
Over the past 52 weeks, Dishman Carbogen Amcis Ltd has traded between a low of ₹129.00 and a high of ₹321.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dishman Carbogen Amcis Ltd has a market capitalization of approximately 2,672.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dishman Carbogen Amcis Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 165.37 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,672.37 Cr, Dishman Carbogen Amcis Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dishman Carbogen Amcis Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dishman Carbogen Amcis Ltd is 165.37. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company reported a consolidated net loss of ₹57.88 crore for the quarter ended June 30, 2026, compared with a profit of ₹23.41 crore in Q1 FY26.
The board approved raising ECB up to CHF 200 million from Aamanya AG, a promoter group company, revising the earlier proposed limit of CHF 135 million.
The board approved FY26 audited results, recommended re-appointing T R Chadha & Co. LLP as statutory auditors, raised the ECB limit to CHF 200 million, and increased the overall borrowing limit to ₹4,000 crore (subject to shareholder approval).
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
228.95 | 2,788 Cr | -82.48 | 2.33 | 0.27 | 3.03 | 3.56 | -1.43 | ||
170.45 | 2,672 Cr | 165.37 | 0.40 | 0.00 | 1.46 | 2.66 | 0.14 | ||
1179.80 | 2,625 Cr | 72.74 | 8.09 | 0.00 | 9.40 | 12.54 | 7.50 | ||
56.00 | 2,467 Cr | 68.44 | 24.62 | 0.02 | 24.55 | 31.50 | 28.93 | ||
248.00 | 2,302 Cr | 742.45 | 2.45 | 0.08 | -10.13 | 0.77 | 0.12 | ||
1108.00 | 2,285 Cr | 34.38 | 3.93 | 0.57 | 11.44 | 14.90 | 7.32 | ||
2055.20 | 2,278 Cr | 49.23 | 9.27 | 0.00 | 16.95 | 17.46 | 9.33 | ||
| Median: 7 Co. | — | 248.00 | 2,467 Cr | 68.44 | 3.93 | 0.02 | 9.40 | 12.54 | 7.32 |
